WFA
SWTX

Wipfli Financial Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Wipfli Financial Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$0 Buy
+13
New +$373 ﹤0.01% 2614

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wipfli Financial Advisors's SWTX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in SpringWorks Therapeutics (SWTX) in Q3 2022: 13 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2614 among its holdings.

148 funds tracked by Wall St. Rank hold SWTX as of Q3 2022.

  • Wipfli Financial Advisors held 13 shares of SpringWorks Therapeutics worth $0 as of Q3 2022.
  • SpringWorks Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • SpringWorks Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2614 holding.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.